Bepotastine
- Generic Name
- Bepotastine
- Brand Names
- Bepreve
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 125602-71-3
- Unique Ingredient Identifier
- HYD2U48IAS
- Background
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
- Indication
用于治疗过敏性鼻炎；荨麻疹；皮肤疾病引起的瘙痒（湿疹•皮炎、痒疹、皮肤瘙痒症）。
- Associated Conditions
- Pruritus
- Associated Therapies
- -
Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT04877678
- Locations
- 🇰🇷
Asan medical center, Seoul, Korea, Republic of
Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Hom, Milton M., OD, FAAO
- Target Recruit Count
- 24
- Registration Number
- NCT01337557
The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- North Texas Institute for Clinical Trials
- Target Recruit Count
- 30
- Registration Number
- NCT01128556
- Locations
- 🇺🇸
North Texas Institute for Clinical Trials, Fort Worth, Texas, United States
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 861
- Registration Number
- NCT00586625
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 107
- Registration Number
- NCT00424398
- Locations
- 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.